Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on precision oncology. The company uses the genetic principle of synthetic lethality to discover and develop cancer therapies, with news centered on its PRMT5 inhibitor program, including vopimetostat, and related oncology combination research.
Recurring updates also cover financial results and business highlights, clinical supply and collaboration activity, investor-conference participation, board and executive appointments, and equity compensation actions under the company’s 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Tango Therapeutics (NASDAQ: TNGX) announced the grant of non-qualified stock options and restricted stock units (RSUs) totaling 637,000 shares and 106,250 RSUs, respectively, to two new employees as part of its 2023 Inducement Plan. This includes 487,500 stock options and 81,250 RSUs awarded to Adam Crystal, M.D., Ph.D., following his appointment as President of Research and Development. The options have an exercise price of $5.20 per share, aligning with the stock's closing price on the grant date, March 1, 2023. The vesting schedules for both options and RSUs are contingent upon continued employment.
Tango Therapeutics (NASDAQ: TNGX), a biotechnology company focused on advanced cancer treatments, announced key investor conference appearances in March 2023. CEO Barbara Weber will participate in the Cowen 43rd Annual Health Care Conference on March 8 at 11:10 AM ET in Boston, and the Barclays Global Healthcare Conference on March 14 at 3:35 PM ET in Miami. Live webcasts of these presentations will be accessible on their website, with replays available for 90 days post-event. Tango Therapeutics aims to leverage synthetic lethality to develop innovative cancer therapies targeting tumor suppressor gene loss.
Tango Therapeutics, a clinical-stage biotechnology firm (NASDAQ: TNGX), has appointed Adam Crystal, M.D., Ph.D. as President of Research and Development. Dr. Crystal will lead preclinical research, drug discovery, and clinical development, working with existing leaders in the company. Tango is currently enrolling patients in a crucial clinical trial and plans to introduce three more programs in the next year. Dr. Crystal's expertise in precision oncology is expected to enhance the advancement of Tango's pipeline, which focuses on synthetic lethal targeting in cancer treatment.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicine, is set to participate in key investor conferences this February. The first event is the Guggenheim Healthcare Talks | 2023 Oncology Conference on February 9, 2023, at 1:00 PM ET in New York. The second is the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET, conducted virtually. Live webcasts will be available on the Company's website, with replays archived post-presentation. Tango is committed to advancing cancer treatment through innovative drug targets and leveraging synthetic lethality principles.
Tango Therapeutics (NASDAQ: TNGX) recently announced significant developments in its clinical pipeline. The U.S. FDA has granted Orphan Drug Designation to TNG908 for treating malignant glioma, enhancing its market exclusivity and providing potential financial incentives. Additionally, the FDA cleared an Investigational New Drug (IND) application for TNG462, a next-generation inhibitor targeting MTAP-deleted cancers, with a clinical trial expected to start in mid-2023. These advancements may broaden the company's strategic options and opportunity to address unmet medical needs in oncology.
Tango Therapeutics (NASDAQ: TNGX) announced the approval of a Clinical Trial Application for TNG908, a PRMT5 inhibitor, by France's ANSM. The company introduced TNG260, targeting STK11-mutant cancers, and TNG348 as a USP1 inhibitor for BRCA1/2-mutant cancers. Aaron Weitzman, M.D., was appointed Chief Medical Officer. Financially, Tango reported Q3 2022 results: collaboration revenue of $6.9 million, a net loss of $29.1 million, and $393.3 million in cash, expected to fund operations into 2025, despite increased R&D and G&A expenses.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company, announced that its CEO, Barbara Weber, will participate in two investor conferences this November. The first event is the H.C. Wainwright 3rd Annual Precision Oncology Conference on November 14 at 11:00 AM ET, followed by the Jefferies London Healthcare Conference on November 15 at 10:20 AM GMT. Both presentations will be available via live webcast on the company’s website, with replays accessible for 90 days.
Tango Therapeutics (NASDAQ: TNGX) announced the selection of three abstracts for poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, scheduled from October 26-28, 2022. The posters will cover the characterization and potential of TNG908 and TNG462, both designed to target MTAP-deleted cancers. Notably, TNG908 is highlighted as a brain-penetrant inhibitor, while TNG462 aims to be a best-in-class option. These presentations showcase Tango's focus on precision cancer therapies.
Tango Therapeutics announced the preclinical development of TNG260, a novel CoREST deacetylase inhibitor targeting STK11-mutant cancers. Presenting three abstracts at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 8-12, 2022, the company aims to demonstrate how TNG260 potentially overcomes immune evasion associated with STK11 mutations, common in non-small cell lung cancers. Plans include submitting an IND application in H1 2023, highlighting the innovative approach to cancer treatment.
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company focused on precision cancer medicines, announced that its CEO, Barbara Weber, M.D., will participate in the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand starting September 12, 2022, at 7:00 AM ET. An archived replay will be accessible on the company’s website for approximately 90 days post-event. Tango Therapeutics specializes in discovering novel drug targets, emphasizing precision oncology for cancer treatment.